2 Blood Biomarkers May Be Used to Monitor Lecanemab’s Efficacy

2 Blood Biomarkers May Be Used to Monitor Lecanemab’s Efficacy

312998

2 Blood Biomarkers May Be Used to Monitor Lecanemab’s Efficacy

The blood levels of two biomarkers of Alzheimer’s disease are significantly associated with changes in brain beta-amyloid deposits and cognitive function in early Alzheimer’s patients treated with lecanemab (BAN2401), according to a new analysis of data from a Phase 2b clinical trial. The results suggest that these blood biomarkers — p-tau181 and beta-amyloid fragments — may be used to monitor lecanemab’s efficacy and help determine treatment dosages. These findings, along with additional data supporting the…

You must be logged in to read/download the full post.